-+ 0.00%
-+ 0.00%
-+ 0.00%

MONTE ROSA THERAPEUTICS - TO CO-FUND PHASE 3 DEVELOPMENT OF MRT-6160 AND SHARE 30% OF PROFITS AND LOSSES IN U.S.

Reuters·10/28/2026 11:00:00

Please log in to view news